Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors
Part A: The purpose of this study is to find the maximum tolerated dose of BMS-777607 in subjects with advanced or metastatic solid tumors

Part B: The purpose of this study is to describe the preliminary activity of BMS-77607 in subjects with advanced or metastatic gastroesophageal cancer, hormone refractory prostate cancer, head and neck squamous cell carcinoma, and type I papillary renal cell carcinoma
Advanced Solid Tumors
DRUG: BMS-777607
Safety and efficacy assessment including vitals signs, physical assessments, and blood tests, will be conducted weekly for the first 3 weeks then every 3 weeks. All assessments will continue for at least 24 months|Tumor assessments, will be conducted every 6 weeks. All assessments will continue for at least 24 months
Pharmacokinetics (PK) of BMS-777607 and its N-oxide metabolite, BMS-797669, will be assessed once weekly for the first 3 weeks|The effects of BMS-777607 on blood pressure (BP), heart rate (HR), will be assessed once weekly for the first 3 weeks then every 3 weeks|Effects on electrocardiogram (ECG), PR interval, will be assessed at base line, at week 3 and at end of treatment|Effects on left ventricular function, will be assessed at baseline and every 3 weeks for 1st 6 weeks then once every 6 months
Part A: The purpose of this study is to find the maximum tolerated dose of BMS-777607 in subjects with advanced or metastatic solid tumors

Part B: The purpose of this study is to describe the preliminary activity of BMS-77607 in subjects with advanced or metastatic gastroesophageal cancer, hormone refractory prostate cancer, head and neck squamous cell carcinoma, and type I papillary renal cell carcinoma